Open in Screener

ELV

Elevance Health Inc

Apr 02 • 04:00PM ET

300.74

+2.24 0.75 %

Healthcare • Healthcare Plans • USA • NYSE

| Held by: VTI VOO IVV SPY VTV XLV VIG VYM VHT RSP

Index	S&P 500	P/E	11.98	EPS (ttm)	25.11	Insider Own	0.28%	Shs Outstand	220.72M	Perf Week	2.21%
Market Cap	66.37B	Forward P/E	10.36	EPS next Y	29.03	Insider Trans	-0.04%	Shs Float	220.09M	Perf Month	3.19%
Enterprise Value	-	PEG	2.38	EPS next Q	10.74	Inst Own	93.16%	Short Float	1.67%	Perf Quarter	-14.21%
Income	5.66B	P/S	0.33	EPS this Y	-14.63%	Inst Trans	2.17%	Short Ratio	1.91	Perf Half Y	-9.60%
Sales	199.12B	P/B	1.51	EPS next Y	12.28%	ROA	4.75%	Short Interest	3.67M	Perf YTD	-14.21%
Book/sh	198.81	P/C	-	EPS next 5Y	4.36%	ROE	13.29%	52W High	458.75 -34.44%	Perf Year	-29.95%
Cash/sh	-	P/FCF	20.91	EPS past 3/5Y	1.27% 6.99%	ROIC	7.53%	52W Low	273.71 9.88%	Perf 3Y	-34.59%
Dividend Est.	7.10 (2.36%)	EV/EBITDA	-	Sales past 3/5Y	8.34% 10.32%	Gross Margin	-	Volatility	2.96% 2.92%	Perf 5Y	-14.99%
Dividend TTM	6.85 (2.28%)	EV/Sales	-	EPS Y/Y TTM	-2.29%	Oper. Margin	4.07%	ATR (14)	9.29	Perf 10Y	112.01%
Dividend Ex-Date	Mar 10, 2026	Quick Ratio	-	Sales Y/Y TTM	12.62%	Profit Margin	2.84%	RSI (14)	50.65	Recom	1.96
Dividend Gr. 3/5Y	10.14% 12.47%	Current Ratio	1.54	EPS Q/Q	36.35%	SMA20	3.33%	Beta	0.48	Target Price	375.80
Payout	27.13%	Debt/Eq	0.75	Sales Q/Q	9.47%	SMA50	-5.02%	Rel Volume	0.62	Prev Close	298.50
Employees	97100	LT Debt/Eq	0.71	Earnings	Apr 22 BMO	SMA200	-8.27%	Avg Volume	1.92M	Price	300.74
IPO	Oct 30, 2001	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.54% -1.07%	Trades		Volume	1,192,401	Change	0.75%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-03-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$358
Jan-08-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$425
Dec-19-25	Downgrade	Deutsche Bank	Buy → Hold	$320
Oct-14-25	Initiated	Goldman	Neutral
Jul-21-25	Downgrade	Argus	Buy → Hold
Jul-18-25	Downgrade	Leerink Partners	Outperform → Market Perform	$310
Apr-15-25	Downgrade	Robert W. Baird	Outperform → Neutral	$529
Mar-17-25	Upgrade	Argus	Hold → Buy	$450
Jan-22-25	Downgrade	Stephens	Overweight → Equal-Weight	$520 → $440
Oct-18-24	Downgrade	Argus	Buy → Hold
Jul-18-24	Downgrade	BofA Securities	Buy → Neutral	$646 → $530
Jun-24-24	Initiated	Morgan Stanley	Overweight	$643
May-30-24	Initiated	Robert W. Baird	Outperform	$649
Mar-06-24	Initiated	Barclays	Overweight	$584
Jul-12-23	Downgrade	Wolfe Research	Outperform → Peer Perform
Apr-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$500 → $571
Apr-21-23	Initiated	Cantor Fitzgerald	Overweight	$547
Mar-28-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$523 → $572
Sep-09-22	Upgrade	BofA Securities	Neutral → Buy	$535 → $575
Aug-22-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$490 → $580

Show Previous Ratings

Apr-02-26 11:54AM	It's not just patients who are sick of fighting health insurers. Doctors are frustrated, too. (MarketWatch)
Apr-01-26 06:33AM	Elevance sidesteps Medicare Advantage sanctions for now (Healthcare Dive)
Mar-31-26 09:00AM	Elevance Health Announces Leadership Appointments to Strengthen Execution and Drive Growth (Business Wire)
04:58AM	Elevance fills slew of mid-level leadership positions (Healthcare Dive)
Mar-30-26 04:30PM	Elevance Health to Hold Conference Call and Webcast to Discuss First Quarter 2026 Results on April 22, 2026 (Business Wire)
10:29AM	Loading…
Mar-29-26 10:29AM	Trump calls for replacing Obamacare with direct payments to Americans (Investing.com)
Mar-10-26 01:41PM	Centene Is the Worst S&P 500 Stock Today. What's Ailing the Health Insurer. (Barrons.com)
Mar-09-26 11:56AM	UNH Deploys AI in Optum Rx to Tackle Pharmacy Fraud and Cost Leakage (Zacks)
Mar-03-26 10:00AM	Elevance Health and National Diaper Bank Network Launch National Pilot to Address Diaper Affordability and Improve Family Health (Business Wire)
04:25AM	CMS threatens Elevance with Medicare Advantage sanctions (Healthcare Dive)
Mar-02-26 05:05PM	These Stocks Are Todays Movers: AES, Norwegian, Elevance, Palantir, Lockheed, Strategy, Berkshire Hathaway, and More (Barrons.com) -8.10%
04:38PM	Stocks to Watch Monday Recap: Norwegian Cruise Line, United Airlines, Lumentum, Elevance (The Wall Street Journal)
04:37PM	Stocks Recover as Iran War Pushes Energy and Defense Stocks Higher (Barchart)
04:01PM	NvidiaCoherent deal, Paramount+ to be combined with HBO Max (Yahoo Finance Video)
01:19PM	Palantir, Energy Stocks Rally, Cruise Lines Tumble On US And Israeli-Iran War: What's Moving Markets Monday? (Benzinga)
12:30PM	Loading…
12:30PM	Elevance Health Stock Sinks After CMS Freezes Medicare Advantage Enrollment (Benzinga)
12:12PM	Stocks to Watch Monday: Norwegian Cruise Line, United Airlines, Lumentum, Elevance (The Wall Street Journal)
11:19AM	Markets Rebound After Initial Selloff Triggered by Middle East Tensions (Barchart)
10:53AM	Analyst Report: Elevance Health, Inc. (Morningstar Research)
09:25AM	Elevance Health Stock Slips. CMS to Halt Enrollment in Prescription Drug Plans. (Barrons.com)
07:35AM	Is Elevance Health Stock Underperforming the Dow? (Barchart)
Feb-27-26 05:45AM	Elevance shuffles C-suite as top Carelon exec departs (Healthcare Dive)
Feb-26-26 03:02PM	Elevance Health Announces Management Changes; CFO Mark Kaye to Expand Responsibilities to Include Carelon and Felicia Norwood to Lead Consolidated Health Benefits Organization (Business Wire)
Feb-25-26 12:42PM	After stints at Nike and Kohls, Elevance Healths CDIO pivots to using tech to bring more delight to health care (Fortune)
12:14PM	Acadia Healthcare Q4 Earnings Beat Estimates on Rising Admissions (Zacks)
Feb-24-26 10:06AM	Is UnitedHealth Stock Underperforming the Dow? (Barchart)
08:45AM	UnitedHealthcare Under Pressure: Can UNH's Core Business Rebound? (Zacks)
Feb-20-26 11:55AM	Select Medical Q4 Earnings Miss Estimates on Increasing Expenses (Zacks)
Feb-19-26 04:02PM	World's Largest Hedge Fund Buys Dell and UnitedHealth, Sells AT&T Stock (Barrons.com)
Feb-18-26 04:50PM	Warren Buffett Disciple Seth Klarman Differs With Mentor On This Magnificent Seven Stock: One Is Buying, One Is Selling (Benzinga)
07:09AM	Loading…
07:09AM	Is Wall Street Bullish or Bearish on Elevance Stock? (Barchart)
Feb-17-26 06:01PM	Glenn Greenberg's Strategic Moves: Elevance Health Inc Sees a -4.37% Portfolio Impact (GuruFocus.com)
Feb-15-26 11:40PM	1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off (StockStory)
Feb-11-26 11:02PM	2 Reasons to Like ELV (and 1 Not So Much) (StockStory)
09:47AM	Humana Earnings Reveal Narrower-Than-Expected Loss. Why the Stock Is Falling. (Barrons.com)
07:04AM	Humana Loss Was Narrower Than Expected. Why the Stock Is Falling. (Barrons.com)
Feb-10-26 05:15PM	Humana Earnings Will Shed More Light on Medicare Prospects (Barrons.com)
12:31PM	Quest Diagnostics Incorporated Q4 2025 Earnings Call Summary (Moby)
08:00AM	Is Elevance Health (ELV) Trading at an Attractive Valuation? (Insider Monkey)
Feb-09-26 02:08PM	Encompass Health Q4 Earnings Beat but Discharges Lag (Zacks)
Feb-06-26 01:32PM	Will Declining Medical Membership Affect Humana's Q4 Earnings? (Zacks)
01:23PM	Centene Incurs Q4 Loss, Revenues Up YoY due to PDP Business Strength (Zacks)
11:31AM	Ensign Group Q4 Earnings Beat Estimates on Growing Occupancy (Zacks)
10:41AM	S&P 500 Health Insurer Dives As ACA Enrollment Implodes (Investor's Business Daily)
09:50AM	Molina Healthcare Incurs a Loss in Q4 as Medical Costs Surge (Zacks)
Feb-04-26 06:46AM	UnitedHealth, CVS, Humana Face Double Trouble As Trump's Medicare Cuts Are Just The StartPBM 'Spread Pricing' Comes Under Fire (Benzinga)
12:38AM	5 Revealing Analyst Questions From Elevance Health's Q4 Earnings Call (StockStory)
Feb-03-26 12:36PM	Can Centene's Q4 Earnings Escape Membership & Cost Headwinds? (Zacks)
09:34AM	Adobe downgraded, Palantir upgraded: Wall Street's top analyst calls (The Fly)
03:08AM	UnitedHealth, CVS, Humana Face Double Trouble As Trump's Medicare Cuts Are Just The Start-PBM 'Spread Pricing' Comes Under Fire (Benzinga)
Feb-02-26 11:18AM	Is the Options Market Predicting a Spike in Elevance Health Stock? (Zacks)
10:47AM	Will Rising Costs Hit Molina's Q4 Earnings? Key Insights Here (Zacks)
Jan-31-26 07:48AM	Barclays Adjusts Elevance Health (ELV) PT to $393 While Maintaining Overweight Rating (Insider Monkey)
Jan-29-26 02:44PM	Health Insurance Stock Could Rebound Off Historically Bullish Signal (Schaeffer's Research)
09:13AM	Healthcare ETFs in Focus as UnitedHealth Rises 4% Post Mixed Q4 Results (Zacks)
02:19AM	Trump's Flat Rate Medicare Advantage Proposal Is 'Shock To The System,' Risking 20% Earnings Hit, Delaying Healthcare Turnaround (Benzinga)
12:37AM	ELV Q4 Deep Dive: Margin Pressures and Membership Shifts Shape 2026 Outlook (StockStory)
Jan-28-26 04:32PM	Stocks Finish Mixed as Fed Keeps Interest Rates Steady (Barchart) +5.86%
04:02PM	Elevance Health Inc (ELV) Q4 2025 Earnings Call Highlights: Strong Financial Performance Amid ... (GuruFocus.com)
01:35PM	Analyst Report: Elevance Health, Inc. (Morningstar Research)
01:01PM	Gold Rallies To $5,300, Memory Stocks Go Wild: What's Moving Markets Wednesday? (Benzinga)
12:35PM	Elevance Health Earnings Add to Medicare Pain. Why The Stock Is Rising Anyway. (Barrons.com)
12:21PM	Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums (Zacks)
11:15AM	Stocks Mixed After the Fed Pauses Rate Cuts (Barchart)
10:20AM	Elevance forecasts 2026 profit below estimates, flags revenue decline (Reuters)
10:09AM	Elevance Health Q4 Earnings Call Highlights (MarketBeat)
10:06AM	US Health Insurer Elevance Health Issues Soft Outlook, Lower Premium Forecast For 2026 (Benzinga)
09:30AM	Elevance Health (ELV) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
07:42AM	Elevance Health Stock Dives Again. Why Earnings Are Adding to Medicare Pain. (Barrons.com)
07:10AM	Elevance Health (ELV) Beats Q4 Earnings Estimates (Zacks)
06:41AM	Elevance Health flags earnings decline amid bleak Medicare Advantage proposal (Investing.com)
06:26AM	Elevance Health (NYSE:ELV) Reports Q4 CY2025 In Line With Expectations But Stock Drops (StockStory)
06:17AM	Elevance Health: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Elevance Health Reports Fourth Quarter and Full Year 2025 Results; Sets Full Year 2026 Outlook (Business Wire)
Jan-27-26 05:33PM	Health Insurers in Shock After Medicare Holds Line on 2027 Payments (The Wall Street Journal) -14.33%
05:12PM	Why shares of UnitedHealth, Humana and other insurers tanked - and took the Dow with them (MarketWatch)
04:54PM	Health Insurers Weigh on the Dow, While S&P 500 Sets Fresh Record (The Wall Street Journal)
04:44PM	Humana, UnitedHealth, CVS Stocks Tumble After Medicare Rates Blow (Barrons.com)
04:44PM	Humana, UnitedHealth, and CVS Stocks Plunge After Setback on Medicare Rates (Barrons.com)
04:38PM	These Stocks Are Todays Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More (Barrons.com)
04:34PM	S&P 500 Posts a Record High on Tech Strength and Solid Corporate Earnings (Barchart)
04:17PM	UnitedHealth, CVS, Other Insurer Stocks Slide on Medicare Proposal (The Wall Street Journal)
04:13PM	Medicare Shock Wipes Out Nearly $100 Billion in Market Value (The Wall Street Journal)
03:27PM	Trump Medicare rates: Healthcare's 'brokenness' isn't going away (Yahoo Finance Video)
12:55PM	S&P 500 Hits New Records, GM Stock Jumps 8% On Earnings: What's Moving Markets Tuesday? (Benzinga)
12:44PM	UnitedHealth Stock Plunges 20%Here's What's Driving the Huge Decline (Investopedia)
11:55AM	Trump Just Shocked Medicare Stocks - Will Seth Klarman Seize This Moment? (Benzinga)
11:42AM	UnitedHealth stock plunges, leads insurers lower after Trump Medicare spending plan surprise (Yahoo Finance)
11:41AM	Why Elevance Health (ELV) Stock Is Falling Today (StockStory)
11:15AM	Broader Market Rallies on Tech Strength and Solid Earnings (Barchart)
10:35AM	Medicare Shock Wipes Out $92 Billion in Market Value (The Wall Street Journal)
10:07AM	Stocks Edge Higher as Chip Makers Rally (Barchart)
09:55AM	Health insurers slide after 2027 Medicare Advantage payments proposal underwhelms (Investing.com)
07:17AM	Medicare Shock Sends UnitedHealth, Humana And CVS Tumbling (Benzinga)
07:16AM	UnitedHealth, Humana, CVS Dive On Flat 2027 Medicare Advantage Rates; UNH Earnings Mixed (Investor's Business Daily)
12:09AM	Wall Street mixed on a wave of corporate earnings as the Federal Reserve meets (Associated Press)
12:09AM	Stocks zigzag on Wall Street following mixed profit reports from UnitedHealth, GM and others (Associated Press Finance)
Jan-26-26 10:19PM	Analyst Report: Elevance Health, Inc. (Morningstar Research)
10:09PM	What To Expect From Elevance Health's (ELV) Q4 Earnings (StockStory)
08:20AM	Tesla, Microsoft, Meta, SanDisk And More: Stocks With Earnings This Week (Benzinga)

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SCHULMAN AMY W	Director	Mar 12 '26	Sale	287.50	26	7,475	218	Mar 23 04:10 PM
Kendrick Charles Morgan JR	EVP & President, Commercial	Mar 06 '26	Sale	284.92	3,196	910,604	11,791	Mar 09 04:45 PM
CHARLES MORGAN KENDRICK	Officer	Mar 06 '26	Proposed Sale	284.92	3,196	910,593		Mar 06 04:17 PM
COLLIS STEVEN H	Director	Mar 05 '26	Buy	289.84	3,000	869,520	3,639	Mar 06 08:03 AM
DeVore Susan D.	Director	Aug 19 '25	Buy	312.15	1,200	374,580	3,502	Aug 21 04:20 PM
BOUDREAUX GAIL	President and CEO	Jul 18 '25	Buy	286.94	8,500	2,438,951	151,020	Jul 18 01:42 PM
Kaye Mark	EVP & CFO	Apr 24 '25	Sale	424.82	4,588	1,949,074	18,977	Apr 25 04:17 PM
Kaye Mark	Officer	Apr 24 '25	Proposed Sale	424.81	4,588	1,949,051		Apr 24 05:10 PM

Open in Screener

GUTS

Fractyl Health Inc

Apr 02 • 04:00PM ET

0.4559

-0.0088 -1.89 %

Healthcare • Biotechnology • USA • NASD

GUTS Fractyl Health Inc daily Stock Chart

Peers: ILMN EXAS CDNA PACB TXG TWST GH CYRX QDEL FLGT

| Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-2.04	Insider Own	19.02%	Shs Outstand	153.37M	Perf Week	-3.66%
Market Cap	72.33M	Forward P/E	-	EPS next Y	-0.55	Insider Trans	0.03%	Shs Float	128.48M	Perf Month	-8.64%
Enterprise Value	52.44M	PEG	-	EPS next Q	-0.16	Inst Own	59.82%	Short Float	4.54%	Perf Quarter	-79.28%
Income	-140.95M	P/S	-	EPS this Y	64.95%	Inst Trans	17.32%	Short Ratio	1.04	Perf Half Y	-68.99%
Sales	0.00M	P/B	7.39	EPS next Y	15.95%	ROA	-122.85%	Short Interest	5.83M	Perf YTD	-79.28%
Book/sh	0.06	P/C	0.89	EPS next 5Y	41.62%	ROE	-744.17%	52W High	3.03 -84.95%	Perf Year	-60.70%
Cash/sh	0.51	P/FCF	-	EPS past 3/5Y	-11.63% -16.69%	ROIC	-213.57%	52W Low	0.38 20.86%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.33% 7.12%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-40.01%	Oper. Margin	-	ATR (14)	0.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.78	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	39.80	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	4.78	EPS Q/Q	44.34%	SMA20	-0.96%	Beta	1.18	Target Price	5.24
Payout	-	Debt/Eq	6.52	Sales Q/Q	-100.00%	SMA50	-26.45%	Rel Volume	0.27	Prev Close	0.46
Employees	100	LT Debt/Eq	5.98	Earnings	Mar 24 AMC	SMA200	-64.83%	Avg Volume	5.63M	Price	0.46
IPO	Feb 02, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	-73.61% -	Trades		Volume	1,503,619	Change	-1.89%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$2
Sep-15-25	Initiated	H.C. Wainwright	Buy	$9
Aug-28-25	Initiated	Ladenburg Thalmann	Buy	$3.60
Feb-28-24	Initiated	Evercore ISI	Outperform
Feb-27-24	Initiated	Morgan Stanley	Overweight	$18
Feb-27-24	Initiated	BofA Securities	Buy	$26

Mar-27-26 09:15AM	Scalable Biotech Manufacturing Unlocks a $14B Market (PR Newswire) -5.20%
Mar-25-26 08:30AM	Fractyl Health, Inc. Common Stock Q4 2025 Earnings Call Summary (Moby) +16.17%
Mar-24-26 11:01PM	Fractyl Health Inc (GUTS) Q4 2025 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com)
04:01PM	Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates (GlobeNewswire)
Mar-17-26 07:00AM	Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026 (GlobeNewswire)
07:00AM	Loading…
Feb-26-26 07:00AM	Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita for Post-GLP-1 Weight Maintenance (GlobeNewswire) -6.19%
Feb-23-26 09:35AM	Fractyl Health, Inc. (GUTS) Loses 77.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-29-26 01:48PM	Fractyl Health Shares Drop, Eyes New FDA Route For Its Lead Product (Benzinga) -68.04%
12:12PM	Fractyl Health Showcases 6-Month REMAIN-1 Data as Revita Curbs Post-GLP-1 Weight Regain (MarketBeat)
07:00AM	Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita After GLP-1 Discontinuation (GlobeNewswire)
Jan-06-26 07:00AM	Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness (GlobeNewswire)
Jan-05-26 07:00AM	Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category (GlobeNewswire) -8.44%
Jan-03-26 06:19AM	Analysts Keep Buy Ratings on Fractyl Health (GUTS) (Insider Monkey)
Dec-31-25 11:12AM	Fractyl Health's REVEAL-1 Study Shows Positive Six-Month Results for Revita in Maintaining Weight and Glycemic Control Post-GLP-1 Use (Insider Monkey)
Dec-15-25 05:45PM	Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones (GlobeNewswire)
07:00AM	Loading…
Dec-02-25 07:00AM	Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita Procedure (GlobeNewswire) +17.95%
Dec-01-25 07:00AM	Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-13-25 12:01AM	Fractyl Health Inc (GUTS) Q3 2025 Earnings Call Highlights: Pioneering Weight Loss Solutions ... (GuruFocus.com)
Nov-12-25 04:05PM	Fractyl Health Reports Third Quarter 2025 Results; Revita Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027 (GlobeNewswire)
Nov-05-25 07:00AM	Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025 (GlobeNewswire)
Oct-21-25 09:20AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Oct-17-25 09:59AM	Fractyl Health Unveils Potent Preclinical Data for Dual GIP/GLP-1 Gene Therapy RJVA-002 for Obesity (Insider Monkey)
Oct-07-25 07:00AM	Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity (GlobeNewswire) -6.80%
Sep-26-25 07:05AM	Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock (GlobeNewswire) +32.67%
07:00AM	Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita Maintained Weight Loss After GLP-1 Discontinuation (GlobeNewswire)
Sep-03-25 07:00AM	Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth (GlobeNewswire)
Aug-13-25 03:12AM	Fractyl Health Inc (GUTS) Q2 2025 Earnings Call Highlights: Financial Discipline and Promising ... (GuruFocus.com)
Aug-12-25 04:05PM	Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-07-25 04:05PM	Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares (GlobeNewswire)
Aug-06-25 04:05PM	Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference (GlobeNewswire) -45.99%
08:30AM	Loading…
08:30AM	Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering (GlobeNewswire)
Aug-05-25 04:15PM	Fractyl Health Announces Proposed Public Offering (GlobeNewswire)
04:02PM	Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure (GlobeNewswire)
Jul-29-25 10:23AM	Canaccord Genuity Reiterates Buy Rating on Fractyl Health (GUTS) (Insider Monkey) -7.61%
Jun-23-25 07:40AM	Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy (GlobeNewswire) -24.77%
07:30AM	Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models (GlobeNewswire)
Jun-18-25 07:00AM	Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing (GlobeNewswire)
Jun-13-25 11:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -5.07%
07:00AM	Fractyl Health to Present New Preclinical Data from its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions (GlobeNewswire)
Jun-04-25 07:00AM	Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita Across its Bariatric and Metabolic Endoscopy Centers Nationwide (GlobeNewswire)
May-19-25 07:00AM	Fractyl Health Advances Rejuva Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes (GlobeNewswire) +25.44%
May-17-25 07:15AM	Fractyl Health Unveils New Rejuva Smart GLP-1 Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025 (GlobeNewswire)
May-13-25 04:05PM	Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates (GlobeNewswire) -13.28%
May-06-25 07:00AM	Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference (GlobeNewswire) -7.98%
Apr-28-25 04:30PM	Fractyl Health to Present Compelling Preclinical Data from its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting (GlobeNewswire)
Apr-02-25 03:34PM	Fractyl Health, Inc. (GUTS): Insider Were Buying In Q1 2025 (Insider Monkey)
Apr-01-25 07:00AM	Fractyl Health Reports Positive Early Data Showing Revita Has Potential to Prevent Weight Regain After GLP-1 Discontinuation (GlobeNewswire) -6.72%
Mar-03-25 04:05PM	Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates (GlobeNewswire)
Feb-24-25 07:00AM	Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025 (GlobeNewswire)
Feb-12-25 09:35AM	After Plunging -19.55% in 4 Weeks, Here's Why the Trend Might Reverse for Fractyl Health, Inc. (GUTS) (Zacks)
Feb-10-25 03:00AM	Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments (Pharma Voice)
Jan-31-25 08:01AM	Fractyl Health Announces Increased Focus on Groundbreaking Revita Weight Maintenance and Rejuva Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025 (GlobeNewswire) -5.15%
Jan-13-25 07:00AM	Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort (GlobeNewswire) +5.41%
Jan-06-25 09:10AM	Heres Why Fractyl Health, Inc. (NASDAQ:GUTS) Is Among the Best Diabetes Stocks to Buy Under $10 (Insider Monkey) -6.36%
Dec-12-24 07:00AM	Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva Smart GLP-1 Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) (GlobeNewswire)
Dec-09-24 07:00AM	Fractyl Health to Present New Preclinical Data from its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) (GlobeNewswire)
Nov-26-24 07:00AM	Fractyl Health to Participate in the Upcoming December Conferences (GlobeNewswire)
Nov-12-24 04:05PM	Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-04-24 04:05PM	Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek 2024 (GlobeNewswire) -9.86% -6.25%
07:00AM	Fractyl Health Presented New Analysis from Pooled Data of Revita Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek 2024 (GlobeNewswire)
Oct-29-24 07:00AM	Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024 (GlobeNewswire) +23.19%
Oct-28-24 07:00AM	Fractyl Health to Present Compelling Weight Maintenance Data from both Revita and Rejuva Platforms at ObesityWeek 2024 (GlobeNewswire) +16.46%
Sep-24-24 07:00AM	Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-03-24 07:00AM	Fractyl Health to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-14-24 04:05PM	Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +5.38%
Aug-12-24 10:53AM	Rising diabetes rates spur growth in weight management solutions (Medical Device Network) +14.61%
Aug-08-24 12:13PM	Fractyl Health touts positive year-long weight loss results for Revita device (Clinical Trials Arena) -6.19%
08:00AM	Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita Endoscopic Procedure (GlobeNewswire)
Aug-07-24 07:00AM	Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024 (GlobeNewswire) -9.77%
Jul-30-24 07:00AM	Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs (GlobeNewswire)
Jun-25-24 09:02AM	FDA expands Fractyl endoscopy trial to include untreated diabetes patients (Medical Device Network) -9.22%
07:00AM	Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day (GlobeNewswire)
Jun-24-24 06:00AM	Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates (GlobeNewswire) +5.76%
Jun-23-24 01:30PM	Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
May-29-24 07:00AM	Fractyl Health to Present New Preclinical Obesity Data from Rejuva Platform at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
May-20-24 06:00AM	Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva at Digestive Disease Week 2024 (GlobeNewswire)
May-13-24 08:56PM	GUTS Stock Earnings: Fractyl Health Beats EPS for Q1 2024 (InvestorPlace) +8.52%
04:00PM	Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
11:41AM	Fractyl Health Says New Revita Data Show Sustained Weight Loss, Glucose Control in Type 2 Diabetes (MT Newswires)
06:00AM	Fractyl Health Presents Clinical Update on Revita German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D) (GlobeNewswire)
May-08-24 06:00AM	Fractyl Health to Present at BofA Securities 2024 Health Care Conference (GlobeNewswire)
May-07-24 06:00AM	Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024 (GlobeNewswire)
Apr-30-24 08:38AM	Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting (GlobeNewswire)
Apr-17-24 03:10PM	The 3 Most Volatile Stocks for Short-Term Traders: April 2024 (InvestorPlace)
Apr-02-24 08:00AM	Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes (GlobeNewswire) -9.53%
Apr-01-24 07:00AM	Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
06:00AM	Fractyl Health Receives FDA IDE Approval for the Revita Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs (GlobeNewswire)
Mar-12-24 02:06PM	UPDATE -- Fractyl Health Announces New Results From Its Rejuva Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity (GlobeNewswire) -10.34%
08:38AM	Fractyl Health Announces New Results From Its Rejuva Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity (GlobeNewswire)
Mar-03-24 01:13PM	Analysts Bet Big on These Beaten-Down IPO Stocks (TipRanks)
Feb-20-24 08:38AM	Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita Pivotal Clinical Trials (GlobeNewswire)
Feb-01-24 08:08PM	Fractyl Health Announces Pricing of Initial Public Offering (GlobeNewswire)

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rajagopalan Harith	Chief Executive Officer	Dec 04 '25	Buy	1.92	10,416	19,999	501,745	Dec 08 07:05 AM

Open in Screener

ALNY

Alnylam Pharmaceuticals Inc

Apr 02 • 04:00PM ET

318.85

-9.88 -3.01 %

Healthcare • Biotechnology • USA • NASD

ALNY Alnylam Pharmaceuticals Inc daily Stock Chart

Peers: VRTX REGN BMRN BIIB IONS SRPT ARWR NTLA CRSP EDIT

| Held by: VTI VO QQQ VUG VXF VOT IBB IWP CGGR QQQM

Index	NDX	P/E	141.27	EPS (ttm)	2.26	Insider Own	0.88%	Shs Outstand	132.38M	Perf Week	-2.84%
Market Cap	42.29B	Forward P/E	30.32	EPS next Y	10.52	Insider Trans	-8.62%	Shs Float	131.46M	Perf Month	-2.58%
Enterprise Value	42.35B	PEG	0.39	EPS next Q	0.96	Inst Own	98.17%	Short Float	3.32%	Perf Quarter	-19.82%
Income	313.75M	P/S	11.39	EPS this Y	187.17%	Inst Trans	-0.71%	Short Ratio	3.16	Perf Half Y	-30.78%
Sales	3.71B	P/B	53.48	EPS next Y	57.19%	ROA	6.73%	Short Interest	4.37M	Perf YTD	-19.82%
Book/sh	5.96	P/C	14.54	EPS next 5Y	78.69%	ROE	73.28%	52W High	495.55 -35.66%	Perf Year	19.50%
Cash/sh	21.93	P/FCF	90.87	EPS past 3/5Y	- -	ROIC	8.98%	52W Low	205.87 54.88%	Perf 3Y	59.17%
Dividend Est.	-	EV/EBITDA	75.99	Sales past 3/5Y	52.98% 49.77%	Gross Margin	81.64%	Volatility	3.27% 3.21%	Perf 5Y	124.84%
Dividend TTM	-	EV/Sales	11.40	EPS Y/Y TTM	209.06%	Oper. Margin	13.51%	ATR (14)	11.28	Perf 10Y	392.13%
Dividend Ex-Date	-	Quick Ratio	2.71	Sales Y/Y TTM	65.19%	Profit Margin	8.45%	RSI (14)	46.98	Recom	1.71
Dividend Gr. 3/5Y	- -	Current Ratio	2.76	EPS Q/Q	310.87%	SMA20	-0.02%	Beta	0.40	Target Price	445.18
Payout	0.00%	Debt/Eq	3.76	Sales Q/Q	84.95%	SMA50	-2.99%	Rel Volume	0.63	Prev Close	328.73
Employees	2500	LT Debt/Eq	3.43	Earnings	Feb 12 BMO	SMA200	-18.92%	Avg Volume	1.38M	Price	318.85
IPO	May 28, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	-29.06% -4.53%	Trades		Volume	872,456	Change	-3.01%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-16-26	Downgrade	Jefferies	Buy → Hold	$330
Jan-28-26	Resumed	Barclays	Overweight	$527
Jan-07-26	Resumed	Oppenheimer	Outperform	$500
Aug-04-25	Upgrade	Wolfe Research	Underperform → Peer Perform
Aug-04-25	Upgrade	Oppenheimer	Perform → Outperform	$490
Jul-30-25	Resumed	Raymond James	Outperform	$370
Jul-21-25	Initiated	Truist	Buy	$385
Mar-31-25	Initiated	Redburn Atlantic	Buy	$353
Mar-24-25	Upgrade	JP Morgan	Neutral → Overweight	$280 → $328
Nov-12-24	Downgrade	Wolfe Research	Peer Perform → Underperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-16-24	Upgrade	Goldman	Neutral → Buy	$198 → $370
Feb-16-24	Downgrade	Goldman	Buy → Neutral	$173
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-08-23	Initiated	Wells Fargo	Equal Weight	$171
Dec-08-23	Initiated	Wells Fargo	Equal Weight
Oct-11-23	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-23	Initiated	Raymond James	Outperform	$208
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$200 → $250
Apr-26-23	Initiated	SMBC Nikko	Neutral	$220

Show Previous Ratings

Mar-30-26 01:00PM	New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management (Business Wire)
Mar-24-26 07:30AM	Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association (Business Wire)
Mar-16-26 09:37AM	Qualcomm, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Mar-10-26 02:49PM	BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz (Benzinga)
08:00AM	Alnylam to Webcast TTR Investor Webinar (Business Wire)
07:19AM	Loading…
Mar-06-26 07:19AM	Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal (Pharmaceutical Technology)
05:13AM	Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs (BioPharma Dive)
Mar-05-26 01:35PM	Tenaya Therapeutics Stock Jumps After New Alnylam Deal (Benzinga)
Mar-04-26 06:57AM	Blackstone puts $400M into Teva, Sanofi gut disease drug (BioPharma Dive)
Mar-02-26 11:39PM	Alnylam Pharmaceuticals Touts AMVUTTRA Momentum, Teases Key Pipeline Readouts at TD Cowen Conf. (MarketBeat)
Mar-01-26 01:33AM	Canaccord Genuity Maintains Buy Rating on Alnylam Pharmaceuticals, Inc. (ALNY) Stock (Insider Monkey)
Feb-24-26 11:43AM	GSK Strikes $1 Billion China RNA Deal (GuruFocus.com)
Feb-23-26 10:00AM	Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference (Business Wire)
Feb-20-26 04:08AM	Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge (Insider Monkey)
Feb-19-26 12:01AM	Analysts Trim Alnylam Pharmaceuticals, Inc. (ALNY) Targets but Keep Faith in 2026 Growth (Insider Monkey)
12:09PM	Loading…
Feb-17-26 12:09PM	RNA-targeting small molecules: a new frontier of drug discovery (Pharmaceutical Technology) +5.79%
Feb-14-26 01:21AM	Is Alnylam Pharmaceuticals (ALNY) One of the Best Upside Stocks to Invest In Right Now? (Insider Monkey)
Feb-13-26 04:30PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) +5.79%
10:19AM	ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down (Zacks)
Feb-12-26 04:31PM	Alnylam Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby)
04:06PM	Alnylam Pharmaceuticals Inc (ALNY) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
12:23PM	Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor (BioPharma Dive)
10:00AM	Here's What Key Metrics Tell Us About Alnylam (ALNY) Q4 Earnings (Zacks)
09:10AM	Alnylam Pharmaceuticals (ALNY) Surpasses Q4 Earnings Estimates (Zacks)
08:22AM	Alnylam: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress (Business Wire)
Feb-11-26 12:57PM	Pharma companies left out of Trump's drug-pricing deals look for way in (Reuters)
Feb-10-26 10:00AM	Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
Feb-09-26 09:15AM	Countdown to Alnylam (ALNY) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-06-26 08:34AM	Do Options Traders Know Something About Alnylam Pharmaceuticals Stock We Don't? (Zacks)
10:00AM	Loading…
Feb-05-26 10:00AM	Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy? (Zacks) -5.89%
Jan-31-26 09:35AM	Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth (Insider Monkey)
Jan-29-26 09:55PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
04:09PM	Phillip Allen Sharp Improved Human Health With Breakthroughs (Investor's Business Daily)
02:27PM	Alnylam Pharmaceuticals Projects 2026 Revenue Around $5.3 Billion as It Focuses on a New Five-Year Strategy (Insider Monkey)
08:00AM	Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Jan-28-26 05:04AM	Should You Buy Alnylam Pharmaceuticals Before Feb. 12? (Motley Fool)
Jan-27-26 08:38AM	Wells Fargo Raises Alnylam (ALNY) Revenue Estimates for Amvuttra Despite Projected Margin Compression (Insider Monkey)
Jan-14-26 08:02AM	JPM26: 2025 a breakout year for rare disease biotechs (Clinical Trials Arena)
Jan-12-26 07:03PM	Alnylam Pharmaceuticals CEO on Development Goals, Profitability (Bloomberg) -6.87%
04:18PM	JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won (Investor's Business Daily)
02:42PM	Alnylam Pharmaceuticals Unveils Alnylam 2030 as Amvuttra Drives Breakout Growth at JPMorgan Conf. (MarketBeat)
01:33PM	Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale (Benzinga)
12:43PM	Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? (Benzinga)
11:15AM	Equity Indexes Recover Early Losses as Precious Metals Reach New Record Highs (Barchart)
10:18AM	JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop (Investor's Business Daily)
06:24AM	AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations (BioPharma Dive)
Jan-11-26 05:00PM	Alnylam Launches "Alnylam 2030" Strategy to Drive Next Era of Growth and Patient Impact (Business Wire)
Jan-09-26 09:09PM	Walmart To Join Nasdaq 100 on Jan. 20 as AstraZeneca Exits (Bloomberg) -6.87%
11:19AM	Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (Reuters)
Jan-08-26 08:00AM	Biotech Stocks' Dark Winter Is Over. What That Means For Investors. (Investor's Business Daily) -5.47%
Jan-07-26 11:02AM	Healthcare and technology stocks are driving up the Nasdaq (MarketWatch)
Jan-05-26 09:15AM	Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-30-25 11:06AM	Stocks Slip as Bond Yields Rise (Barchart)
Dec-19-25 06:18AM	Here's Why Alnylam Pharmaceuticals (ALNY) Surged in Q3 (Insider Monkey)
Dec-18-25 05:15AM	Alnylam plans $250m investment in Norton manufacturing facility, US (Pharmaceutical Technology)
Dec-17-25 08:00AM	Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics (Business Wire)
Dec-15-25 12:15PM	MicroStrategy retains place in key index despite delisting threats (TheStreet)
10:05AM	Lululemon Set to Exit Nasdaq 100 as Index Adds New Members (GuruFocus.com)
09:11AM	Western Digital stock rises after inclusion in Nasdaq-100 Index (Investing.com)
07:03AM	200% Surge? These 6 Stocks Just Crashed the Nasdaq 100 Party (GuruFocus.com)
Dec-13-25 11:04AM	Walmart was too late for a Nasdaq-100 spot - but these 6 stocks made the cut (MarketWatch)
Dec-12-25 08:21PM	Bitcoin hoarding company Strategy remains in Nasdaq 100 (Reuters)
08:30AM	Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options (Zacks)
Dec-11-25 07:00AM	Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027 (Business Wire)
Dec-07-25 02:45AM	Is Alnylam Pharmaceuticals a Millionaire Maker? (Motley Fool)
Dec-05-25 04:34PM	The S&P 500 Is Due to Rebalance on Friday. What Could Change. (Barrons.com) -6.13%
Dec-03-25 08:00AM	Alnylam Pharmaceuticals Announces Changes to Board of Directors (Business Wire)
Dec-02-25 08:11AM	These Stocks Could Join the S&P 500 in Rebalancing (Barrons.com)
08:02AM	How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint (Investor's Business Daily)
Dec-01-25 05:09PM	These Stocks Could Join the S&P 500 in Rebalancing (Barrons.com)
03:47PM	CRH, Vertiv, Ares, Alnylam Could Be Added to S&P 500 Friday in Rebalancing (Barrons.com)
Nov-22-25 08:00AM	S&P 500 Retailer Leads Five Resilient Stocks After Nvidia-Led Market Sell-Off (Investor's Business Daily)
Nov-20-25 01:39PM	High-Flying Biotech Stock Sets Up After 96% Pop; Profitability In Sight As Key Drug Sales Double (Investor's Business Daily)
01:35PM	Highflying Biotech Stock Sets Up After 96% Pop; Annual Profit In Sight As Key Drug Sales Double (Investor's Business Daily)
Nov-18-25 09:40AM	Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-13-25 09:07AM	Alnylam Pharmaceuticals (ALNY) Surged on Strong Growth and Optimistic Revenue Outlook (Insider Monkey)
03:00AM	RNAi looked doomed to fail until Alnylams science chief found a way (Pharma Voice)
Nov-11-25 05:40AM	Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money (Motley Fool)
Nov-08-25 04:57PM	New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM (Business Wire)
Nov-04-25 11:28AM	Top 20 biopharma companies Q3 2025 market cap up 4% despite headwinds (Pharmaceutical Technology)
08:00AM	Alnylam to Webcast Presentations at Upcoming November Investor Conferences (Business Wire)
Oct-31-25 10:37AM	ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales (Zacks)
08:04AM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Oct-30-25 04:24PM	Alnylam Pharmaceuticals Inc (ALNY) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -6.65%
04:19PM	Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
01:13PM	Earnings roundup: Alnylams down day, Neurocrines head scratch and Biogens low quality win (BioPharma Dive)
10:30AM	Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics (Zacks)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:49AM	Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
09:15AM	Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates (Zacks)
08:16AM	Alnylam: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress (Business Wire)
Oct-29-25 01:47PM	Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect (Zacks)
11:27AM	Amgen's Q3 Earnings in the Cards: Here's What to Expect (Zacks)
Oct-28-25 04:21PM	These Are The 5 Best Stocks To Buy Now Or Watch (Investor's Business Daily)
11:52AM	Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? (Zacks)
09:15AM	Exploring Analyst Estimates for Alnylam (ALNY) Q3 Earnings, Beyond Revenue and EPS (Zacks)
Oct-27-25 12:44PM	ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards? (Zacks)
10:00AM	Krystal Biotech, Inc. (KRYS) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Garg Pushkal	EVP Chief R&D	Mar 05 '26	Sale	323.96	2,404	778,812	18,693	Mar 06 04:13 PM
Garg Pushkal	EVP Chief R&D	Mar 04 '26	Sale	323.08	2,309	745,984	21,097	Mar 06 04:13 PM
Greenstreet Yvonne	Chief Executive Officer	Mar 04 '26	Sale	323.08	2,933	947,581	95,695	Mar 06 04:13 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Mar 04 '26	Sale	323.08	2,468	797,351	61,805	Mar 06 04:12 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Mar 04 '26	Sale	323.08	2,309	745,984	34,297	Mar 06 04:12 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 05 '26	Sale	323.98	658	213,177	20,569	Mar 06 04:11 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 04 '26	Sale	323.08	633	204,508	21,227	Mar 06 04:11 PM
Fitzgerald Kevin Joseph	Officer	Mar 05 '26	Proposed Sale	323.69	658	212,988		Mar 05 04:04 PM
Garg Pushkal	Officer	Mar 05 '26	Proposed Sale	323.69	2,404	778,151		Mar 05 04:03 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Mar 02 '26	Sale	327.65	2,206	722,801	64,273	Mar 04 07:31 PM
Garg Pushkal	EVP Chief R&D	Mar 03 '26	Sale	319.74	1,775	567,546	23,406	Mar 04 07:31 PM
Garg Pushkal	EVP Chief R&D	Mar 02 '26	Sale	327.66	1,717	562,585	25,181	Mar 04 07:31 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 03 '26	Sale	319.73	1,652	528,189	21,860	Mar 04 07:30 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 02 '26	Sale	327.65	1,598	523,584	23,512	Mar 04 07:30 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Mar 02 '26	Sale	327.65	1,598	523,584	36,606	Mar 04 07:30 PM
Greenstreet Yvonne	Chief Executive Officer	Mar 02 '26	Sale	327.65	6,799	2,227,698	98,628	Mar 04 07:29 PM
Fitzgerald Kevin Joseph	Officer	Mar 03 '26	Proposed Sale	321.37	1,652	530,903		Mar 03 04:49 PM
Garg Pushkal	Officer	Mar 03 '26	Proposed Sale	321.37	1,775	570,432		Mar 03 04:11 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 27 '26	Option Exercise	0.00	5,921	0	91,583	Mar 02 04:10 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 27 '26	Option Exercise	0.00	1,908	0	61,710	Mar 02 04:09 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 27 '26	Option Exercise	0.00	1,666	0	33,435	Mar 02 04:09 PM
Garg Pushkal	EVP Chief R&D	Feb 27 '26	Option Exercise	0.00	1,908	0	26,756	Mar 02 04:08 PM
Garg Pushkal	EVP Chief R&D	Feb 27 '26	Sale	331.34	4,627	1,533,100	22,129	Mar 02 04:08 PM
Garg Pushkal	Officer	Feb 27 '26	Proposed Sale	331.34	4,627	1,533,107		Feb 27 04:05 PM
Garg Pushkal	EVP Chief R&D	Feb 13 '26	Sale	310.08	2,242	695,201	24,848	Feb 17 07:28 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 13 '26	Sale	310.08	6,958	2,157,542	85,662	Feb 17 07:27 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 13 '26	Sale	310.08	1,959	607,448	31,769	Feb 17 07:27 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 17 '26	Sale	331.96	2,041	677,532	21,264	Feb 17 07:26 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 13 '26	Sale	310.08	1,959	607,448	23,305	Feb 17 07:26 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 13 '26	Sale	310.08	2,242	695,201	59,802	Feb 17 07:26 PM
Fitzgerald Kevin Joseph	Officer	Feb 17 '26	Proposed Sale	331.96	2,041	677,532		Feb 17 04:10 PM
Garg Pushkal	EVP Chief R&D	Jan 12 '26	Sale	362.87	1,510	547,929	22,511	Jan 14 04:23 PM
Greenstreet Yvonne	Chief Executive Officer	Jan 12 '26	Sale	362.86	9,577	3,475,157	78,411	Jan 14 04:23 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Jan 12 '26	Sale	362.87	2,780	1,008,766	57,465	Jan 14 04:22 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Jan 12 '26	Sale	362.87	1,510	547,927	29,728	Jan 14 04:22 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Jan 13 '26	Sale	370.33	2,290	848,065	21,264	Jan 14 04:21 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Jan 12 '26	Sale	362.87	1,510	547,927	23,554	Jan 14 04:21 PM
Fitzgerald Kevin Joseph	Officer	Jan 13 '26	Proposed Sale	369.10	2,290	845,239		Jan 13 04:32 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 26 '25	Option Exercise	106.40	4,697	499,756	70,106	Dec 01 04:10 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 17 '25	Option Exercise	119.13	8,161	972,220	33,392	Nov 19 04:05 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 17 '25	Sale	452.18	12,128	5,483,990	21,264	Nov 19 04:05 PM
Fitzgerald Kevin Joseph	Officer	Nov 17 '25	Proposed Sale	449.00	12,128	5,445,472		Nov 17 04:04 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 12 '25	Option Exercise	115.94	15,650	1,814,393	81,059	Nov 14 04:13 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 13 '25	Option Exercise	119.13	10,000	1,191,300	75,409	Nov 14 04:13 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 12 '25	Sale	453.69	15,650	7,100,322	65,409	Nov 14 04:13 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 13 '25	Sale	451.27	10,000	4,512,682	65,409	Nov 14 04:13 PM
Greenstreet Yvonne	Officer	Nov 12 '25	Proposed Sale	453.10	25,650	11,621,956		Nov 12 04:03 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Oct 02 '25	Sale	452.05	3,821	1,727,284	54,052	Oct 03 05:14 PM
Greenstreet Yvonne	Chief Executive Officer	Oct 02 '25	Sale	452.05	8,924	4,034,085	65,409	Oct 03 05:14 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Oct 02 '25	Sale	452.05	1,405	635,126	27,438	Oct 03 05:14 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Oct 02 '25	Sale	452.05	2,441	1,103,451	25,231	Oct 03 05:13 PM
Garg Pushkal	EVP Chief R&D	Oct 03 '25	Sale	451.48	3,022	1,364,387	20,221	Oct 03 05:12 PM
Garg Pushkal	EVP Chief R&D	Oct 02 '25	Sale	452.05	2,937	1,327,675	23,243	Oct 03 05:12 PM
Garg Pushkal	Officer	Oct 03 '25	Proposed Sale	451.00	3,022	1,362,922		Oct 03 04:08 PM
Reitan Colleen F	Director	Sep 09 '25	Option Exercise	100.65	18,000	1,811,700	18,775	Sep 11 04:05 PM
Reitan Colleen F	Director	Sep 09 '25	Sale	467.60	18,000	8,416,730	775	Sep 11 04:05 PM
Reitan Colleen F	Director	Sep 09 '25	Proposed Sale	461.12	18,000	8,300,070		Sep 09 04:05 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Aug 29 '25	Sale	448.37	3,474	1,557,649	25,992	Sep 02 04:10 PM
Tanguler Tolga	Officer	Aug 29 '25	Proposed Sale	452.22	3,474	1,571,012		Aug 29 04:05 PM
Garg Pushkal	EVP Chief R&D	Aug 19 '25	Sale	458.41	1,455	666,987	20,221	Aug 19 05:28 PM
Garg Pushkal	EVP Chief R&D	Aug 18 '25	Sale	453.27	1,396	632,759	21,676	Aug 19 05:28 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Aug 18 '25	Sale	453.27	1,396	632,759	29,466	Aug 19 05:28 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Aug 18 '25	Sale	453.27	2,274	1,030,727	50,121	Aug 19 05:27 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 18 '25	Sale	453.27	6,979	3,163,346	56,221	Aug 19 05:27 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Aug 18 '25	Sale	453.27	1,396	632,759	22,719	Aug 19 05:26 PM
BONNEY MICHAEL W	Director	Aug 18 '25	Option Exercise	70.20	11,250	789,750	28,054	Aug 19 05:26 PM
BONNEY MICHAEL W	Director	Aug 18 '25	Sale	450.00	11,250	5,062,500	16,804	Aug 19 05:26 PM
Garg Pushkal	Officer	Aug 19 '25	Proposed Sale	457.00	1,455	664,935		Aug 19 04:03 PM
BONNEY MICHAEL W	Director	Aug 18 '25	Proposed Sale	450.00	11,250	5,062,500		Aug 18 04:08 PM
Ausiello Dennis A	Director	Aug 14 '25	Option Exercise	131.34	31,448	4,130,478	32,359	Aug 15 04:05 PM
Ausiello Dennis A	Director	Aug 14 '25	Sale	436.58	31,448	13,729,536	911	Aug 15 04:05 PM
Ausiello Dennis A	Director	Aug 14 '25	Proposed Sale	433.59	31,448	13,635,538		Aug 14 04:17 PM
Greenstreet Yvonne	Chief Executive Officer	May 30 '25	Option Exercise	118.46	31,640	3,748,149	80,588	Jun 03 04:10 PM
Greenstreet Yvonne	Chief Executive Officer	Jun 02 '25	Option Exercise	118.73	19,297	2,291,057	68,245	Jun 03 04:10 PM
Greenstreet Yvonne	Chief Executive Officer	May 30 '25	Sale	304.39	31,640	9,630,902	48,948	Jun 03 04:10 PM
Greenstreet Yvonne	Chief Executive Officer	Jun 02 '25	Sale	306.00	19,297	5,904,882	48,948	Jun 03 04:10 PM
Greenstreet Yvonne	Officer	Jun 02 '25	Proposed Sale	303.10	19,297	5,848,824		Jun 02 04:08 PM
Greenstreet Yvonne	Officer	May 30 '25	Proposed Sale	304.39	31,640	9,630,902		May 30 04:18 PM
SHARP PHILLIP A	Director	May 30 '25	Proposed Sale	300.00	11,250	3,375,000		May 30 04:10 PM
BONNEY MICHAEL W	Director	May 15 '25	Option Exercise	131.21	11,250	1,476,112	28,054	May 19 04:17 PM
BONNEY MICHAEL W	Director	May 15 '25	Sale	277.71	11,250	3,124,217	16,804	May 19 04:17 PM
BONNEY MICHAEL W	Director	May 15 '25	Proposed Sale	269.53	11,250	3,032,212		May 15 04:03 PM
Reitan Colleen F	Director	Apr 16 '25	Sale	232.86	36	8,383	0	May 12 04:05 PM

ELV

Elevance Health Inc

GUTS

Fractyl Health Inc

ALNY

Alnylam Pharmaceuticals Inc

Upgrade your Finviz experience